Joseph Davis Selected Research

CP8863

10/2010

Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joseph Davis Research Topics

Disease

2	Atherosclerosis 09/2016 - 09/2014
2	Coronary Artery Disease (Coronary Atherosclerosis) 09/2016 - 09/2014
1	Poisoning 03/2013
1	Leiomyoma (Uterine Fibroids) 10/2010

Drug/Important Bio-Agent (IBA)

2	LipidsIBA 09/2016 - 09/2014
2	Simvastatin (Zocor)FDA LinkGeneric 09/2016 - 09/2014
2	Colestipol (Colestid)FDA LinkGeneric 09/2016 - 09/2014
2	Lovastatin (Mevacor)FDA LinkGeneric 09/2016 - 09/2014
2	Niacin (Nicotinic Acid)FDA LinkGeneric 09/2016 - 09/2014
1	LDL CholesterolIBA 09/2016
1	Ezetimibe (Zetia)FDA Link 09/2016
1	oxidized low density lipoproteinIBA 09/2016
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2014
1	FatsIBA 09/2014
1	Narcotics (Narcotic Analgesics)IBA 03/2013
1	CP 8947IBA 10/2010
1	CP8863IBA 10/2010
1	Progesterone FDA LinkGeneric 10/2010
1	Progesterone Receptors (Progesterone Receptor)IBA 10/2010
1	Alkaline PhosphataseIBA 10/2010

Therapy/Procedure

3	Therapeutics 09/2016 - 10/2010